Back

Vitamin D promotes DNase1L3 to degrade ecDNA and inhibit the malignant progression of hepatocellular carcinoma

Sun, T.; Zhang, H.; Qin, L.-n.; Li, Q.-q.; Wu, T.; Zhang, L.; Wang, K.-w.; Cheng, S.-b.; Shi, Y.; Feng, Y.-q.; Han, J.-x.; Li, Y.-n.; Li, Z.-y.; Liu, H.-j.

2023-09-01 cancer biology
10.1101/2023.08.30.555532 bioRxiv
Show abstract

Extrachromosomal DNA (ecDNA) is an important carrier of oncogene amplification. However, the degradation mechanism of ecDNA is not well understood. We found that endogenous natural molecular vitamin D (VD) reduces ecDNA and inhibits the progression of hepatocellular carcinoma (HCC). VD reduces ecDNA depending on its transporter GC, which interacts with the endonuclease DNase1L3 and stabilize its protein level. DNase1L3 with its lipophilic region on N-terminus exhibiting an affinity towards lipid droplets (LDs) demonstrates direct degradation effect on ecDNA. Intranuclear LDs are abundantly distributed around ecDNA, DNase1L3 therefore shows an affinity for ecDNA owing to its lipophilic region. VD, as a lipid-soluble molecule, can increase the size of LDs and improve the degradation of DNase1L3 on ecDNA. Consequently, we designed two mRNA-based therapeutics, DNase1L3 and GC-DNase, both of which had an anti-tumor effect on PDX models. The above results showed that treatments targeting ecDNA in cancer are prospective in clinical practice.

Matching journals

The top 8 journals account for 50% of the predicted probability mass.

1
eLife
● 5828 papers in training set
Top 6%
12.8%
Similar papers in this journal
2
Advanced Science
○ 286 papers in training set
Top 0.4%
9.0%
Similar papers in this journal
3
Science Advances
● 1243 papers in training set
Top 2%
7.4%
Similar papers in this journal
4
Nature Communications
○ 5641 papers in training set
Top 23%
6.8%
Similar papers in this journal
5
Cell Death & Disease
147 papers in training set
Top 0.2%
6.8%
6
Cell Discovery
○ 57 papers in training set
Top 0.2%
3.6%
7
Theranostics
● 37 papers in training set
Top 0.1%
3.5%
8
Redox Biology
○ 70 papers in training set
Top 0.4%
2.7%
50% of probability mass above
9
iScience
○ 1154 papers in training set
Top 11%
2.4%
10
Science China Life Sciences
○ 29 papers in training set
Top 0.2%
2.0%
11
Cell Research
○ 51 papers in training set
Top 0.5%
2.0%
12
Communications Biology
○ 993 papers in training set
Top 12%
1.9%
13
Nucleic Acids Research
◐ 1281 papers in training set
Top 8%
1.7%
14
Proceedings of the National Academy of Sciences
● 2444 papers in training set
Top 27%
1.7%
15
Cell Death & Differentiation
○ 48 papers in training set
Top 0.6%
1.5%
16
Cell Reports
○ 1498 papers in training set
Top 20%
1.5%
17
Clinical and Translational Medicine
○ 31 papers in training set
Top 0.5%
1.1%
18
Molecular Cancer
○ 16 papers in training set
Top 0.2%
1.1%
19
Acta Biochimica et Biophysica Sinica
● 23 papers in training set
Top 0.4%
1.1%
20
Protein & Cell
◐ 25 papers in training set
Top 0.4%
1.1%
21
Journal of Biological Chemistry
○ 690 papers in training set
Top 8%
1.0%
22
Signal Transduction and Targeted Therapy
○ 30 papers in training set
Top 0.5%
1.0%
23
Cell Proliferation
○ 12 papers in training set
Top 0.2%
1.0%
24
Cancer Research
● 130 papers in training set
Top 3%
0.9%
25
Cancer Letters
○ 35 papers in training set
Top 1%
0.9%
26
Molecular Therapy - Nucleic Acids
○ 25 papers in training set
Top 0.6%
0.9%
27
Genomics, Proteomics & Bioinformatics
188 papers in training set
Top 2%
0.9%
28
EMBO Reports
○ 263 papers in training set
Top 7%
0.9%
29
Life Science Alliance
● 285 papers in training set
Top 9%
0.6%
30
Molecular Therapy
○ 81 papers in training set
Top 2%
0.6%

"Similar papers" are the closest papers from that journal in the model's embedding space. They show what the match is built on, but the ranking comes mostly from a classifier over the whole training set, not from these examples alone.